dronedarone / Generic mfg. - LARVOL DELTA

Dronedarone vs class Ic agents for early AF: Protocol for the DRIVE-AF randomized clinical trial. (PubMed, Heart Rhythm O2) - P4 | "Participants will be randomized (1:1) to receive either dronedarone (400 mg twice daily) or standard-of-care class Ic agents (flecainide or propafenone) for 12 months. By establishing comparative efficacy and safety, this study aims to refine international standards for pharmacologic rhythm control in early AF. ClinicalTrials.gov identifier: NCT07270848."

Clinical • Journal • Atrial Fibrillation • Cardiovascular

Comparison of the Efficacy and Safety of Dronedarone and Amiodarone for Preventing Atrial Fibrillation Recurrence After Catheter Ablation: A Meta-Analysis of Reconstructed Time-to-Event Data (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Atrial Fibrillation • Cardiovascular

Dronedarone Versus Amiodarone for Preventing Atrial Fibrillation Recurrence After Catheter Ablation: A GRADE-Assessed Meta-Analysis of Reconstructed Time-to-Event Data With Trial Sequential Analysis. (PubMed, Cardiol Rev) - "Dronedarone was associated with lower risks of QTc-interval prolongation (RR 0.39; 95% CI, 0.19-0.80) and thyroid dysfunction (RR 0.37; 95% CI, 0.24-0.57) but higher risks of gastrointestinal (RR 7.72; 95% CI, 2.10-28.37) and dermatologic (RR 4.20; 95% CI, 1.06-16.53) adverse events. Dronedarone and amiodarone appear equally effective at preventing AF recurrence after catheter ablation but differ in safety, so selection should be individualized according to patient-specific tolerability and toxicity risk."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders

Comparative clinical effectiveness and safety of amiodarone versus dronedarone in patients with atrial fibrillation (ESC 2026) - "In this real-world cohort of patients with atrial fibrillation, dronedarone was associated with lower risks of mortality, hospitalization, major adverse cardiovascular events, thyroid dysfunction and liver disease compared with amiodarone."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Ischemic stroke • Myocardial Infarction

One-year outcomes of rhythm control strategies for atrial fibrillation among patients with cardiac amyloidosis and heart failure (ESC 2026) - "Objective We compared clinical outcomes between catheter ablation and antiarrhythmic drug therapy for atrial fibrillation in patients with amyloidosis and heart failure Methods We conducted a retrospective cohort study using TriNetX Research Network, identifying 1,541 patients who underwent catheter ablation and 8,677 patients treated with antiarrhythmics (amiodarone, sotalol, dofetilide, dronedarone) for atrial fibrillation with documented amyloidosis and heart failure. Stroke rates were similar (6.9% vs 8.2%, p=0.232). Catheter ablation was associated with higher cardioversion requirements (22.1% vs 14.1%, p<0.001) Conclusion In patients with cardiac amyloidosis, heart failure, and atrial fibrillation, catheter ablation was associated with decreased mortality compared to antiarrhythmic drugs, along with significantly fewer heart failure events and hospitalizations."

Clinical • Atrial Fibrillation • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Ventricular Tachycardia

Extra-pulmonary vein drivers as a potential mechanism of the antiarrhythmic drug-resistant atrial fibrillation after catheter ablation: Digital twin-guided virtual drug test (ESC 2026) - "Among patients who required AADs for AA recurrence after PVI, limited suppression of stable PS area under Virtual AADs, but not restitution response, predicts 3-year Clinical AA recurrence. These findings suggest that persistent extra-PV PS drivers may contribute to AAD-resistant AA recurrence after PVI."

Atrial Fibrillation • Cardiovascular

Comment on "The Antiarrhythmic Drugs Dronedarone and Amiodarone Exhibit Potent In Vitro and In Vivo Activity Against Clostridioides difficile". (PubMed, Int J Antimicrob Agents) - No abstract available

Journal • Preclinical

Cryo-InitialAF: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=320 | Completed | Sponsor: Ruijin Hospital | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Aug 2025

Trial completion • Trial completion date • Atrial Fibrillation • Cardiovascular

Effects of Antiarrhythmics on Cardiac Phenotype and Redox Balance in Spontaneously Hypertensive Rats. (PubMed, Int J Mol Sci) - "Male SHRs were treated for 4 weeks with dronedarone, amiodarone, or dofetilide. Treatments decreased HSP70 expression, while increasing SERCA2 expression, particularly in the dofetilide group. Class III antiarrhythmic drugs differentially affect cardiac function, redox balance, calcium handling, and myocardial remodeling in hypertension, which may contribute to their distinct antiarrhythmic and cardioprotective properties."

Journal • Preclinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Raman spectroscopy combined with machine learning algorithms for discrimination of cancer cell death pathways: Apoptosis and pyroptosis. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "This study demonstrates that Raman spectroscopy combined with machine learning algorithms can accurately predict cancer cell death pathways, and that visualization techniques can be used to identify biomarkers associated with these pathways, providing reliable technical support for research into drug mechanisms of action."

Journal • Oncology

Prescription of colchicine and NSAIDs for acute gout flares in severe chronic kidney disease and colchicine in major drug–drug interactions: evidence from an electronic health-record based gout register (EULAR 2026) - "Strong inhibitors included atazanavir, clarithromycin, cobicistat, darunavir, fluconazole, ketoconazole, lopinavir, ritonavir, nirmatrelvir–ritonavir, voriconazole, and ciclosporin. Moderate to weak inhibitors included erythromycin, verapamil, amiodarone, diltiazem, and dronedarone...Conclusions Colchicine was frequently prescribed for acute gout flares in patients with severe chronic kidney disease despite society guideline recommendations, although co-prescription with strong CYP3A4 or P-glycoprotein inhibitors was uncommon. These findings suggest partial adherence to recommendations and warrant further evaluation of colchicine safety in patients with severe chronic kidney disease."

Chronic Kidney Disease • Gout • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • CYP3A4

Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System. (PubMed, Medicine (Baltimore)) - "Four cardiovascular system drugs (12.12%) included amiodarone (ROR = 41.92), dronedarone (ROR = 10.25), and simvastatin (ROR = 6.94). Four respiratory system drugs (12.12%) included indacaterol (ROR = 6.87), salmeterol/fluticasone (ROR = 4.30), and olodaterol (ROR = 3.76). Four antipathogenic microbial drugs (12.12%) included nitrofurantoin (ROR = 22.92), sulfasalazine (ROR = 5.69), and hydroxychloroquine (ROR = 3.51). Six other drugs (18.18%) included iodine-131 (ROR = 19.72), calcium carbonate (ROR = 8.59), and tamsulosin (ROR = 7.48)...The 3 drugs associated with the greatest PF risk were amiodarone, bleomycin, and nitrofurantoin. These findings highlight potential pharmacovigilance signals that warrant clinical vigilance and further validation through prospective studies."

Adverse events • Journal • Real-world evidence • Cardiovascular • Cough • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases

A simple, high-throughput LC-MS/MS method for the simultaneous quantification of four antiarrhythmic drugs and two metabolites: large-scale application to 622 patient samples. (PubMed, Talanta) - "Here, we developed and validated a simple, high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of four commonly prescribed AADs-amiodarone, dronedarone, flecainide, and propafenone-and two metabolites, noramiodarone and debutyldronedarone, in human serum, and applied it to routine clinical samples. AAD concentrations showed substantial inter-individual variability at identical daily doses, and high proportions of samples were below the therapeutic ranges, supporting the potential utility of routine AAD TDM. This LC-MS/MS method provides a rapid, robust, and clinically practical platform for routine individualized AAD TDM in real-world serum samples with complex matrices."

Journal • Cardiovascular • Psychiatry

The present and future of antiarrhythmic drugs. (PubMed, JRSM Cardiovasc Dis) - "Flecainide, propafenone, and dronedarone have demonstrated their reliable efficacy and safety, even in patients with structural heart disease, which should allow clinicians to reduce their reliance on amiodarone. Previous concerns regarding the proarrhythmic risk of dofetilide and ibutilide are currently managed through careful patient selection and adequate QT interval monitoring. Novel targeted AADs are advancing through the development pipeline, of which etripamil and landiolol have already been approved. Other emerging drugs, such as SK channel blockers (AP30663 and AP31969), RyR2 blockers, CaMKII inhibitors, and TASK-1 blockers (doxapram), are aligned with the new paradigm of atrial fibrillation that focuses on triggers and re-entry...Developing concepts such as atrial cardiomyopathy allows clinicians to characterize substrate objectively, in order to assess disease severity and individualize antiarrhythmic treatment. The future of antiarrhythmic therapy will be..."

Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Heart Failure

Comparative effectiveness of existing medical therapy for atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM) (HEART FAILURE 2026) - "Patients were grouped by post-DCCV outpatient therapy: amiodarone, non-amiodarone AADs (sotalol, dofetilide, dronedarone), or non-AAD therapy (e.g., beta-blockers, calcium channel blockers). Short-term AF recurrence on non-ablative therapy is high, regardless of therapeutic strategy. Amiodarone and non-AAD strategies were more frequent in patients with smaller atria and lower prevalence of prior AF compared to non-amiodarone AADs, reflecting use later in disease course. Use of amiodarone as often as non-AADs in earlier AF-HCM may reflect a preference for immediate stabilization, followed by other AADs with fewer long-term side effects, especially in inpatient settings."

HEOR • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Hepatic ACSL4 Loss Boosts Endogenous Gamma-Glutamylcysteine to Alleviate Alcoholic Liver Disease. (PubMed, Antioxidants (Basel)) - "Dronedarone, identified as a novel compound targeting ACSL4, demonstrated efficacy in ameliorating the progression of ALD. Overall, these findings elucidate a novel mechanism wherein ACSL4 modulates antioxidant responses via a small bioactive peptide, highlighting ACSL4 as a potential therapeutic target for ALD."

Journal • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • Metabolic Disorders • ACSL4

Delayed Recognition of Dronedarone-Induced Interstitial Lung Disease in a Patient with Membranous Nephropathy on Immunosuppression (NKF-SCM 2026) - "Dronedarone, a benzofuran antiarrhythmic structurally related to amiodarone, has been linked to rare pulmonary toxicity...METHODS/CASE SUMMARY A 73-year-old man with biopsy-confirmed MN on prednisone and repository corticotropin (ACTH) presented with 2 weeks of worsening dyspnea and cough...Dronedarone was discontinued, and high‑dose intravenous methylprednisolone was started...This effect can be masked by immunosuppressive agents used in many conditions, delaying timely recognition, as in this case. Clinicians should consider routine pulmonary surveillance in high‑risk patients to enable earlier detection."

Clinical • Cough • Glomerulonephritis • Interstitial Lung Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases

Comparison of the effectiveness and safety of dronedarone and amiodarone for preventing recurrence after catheter ablation of atrial fibrillation: an open-label randomized controlled trial. (PubMed, Europace) - "Therapy with dronedarone during the blanking period after AF ablation was associated with a similar recurrence rate but a superior safety profile compared to amiodarone."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders

Retrospective Analysis of Dronedarone Versus Amiodarone on Outcomes Following Radiofrequency Ablation for Atrial Fibrillation. (PubMed, Br J Hosp Med (Lond)) - "Dronedarone and amiodarone are similarly effective in reducing the AF recurrence after RFA. However, dronedarone is associated with a lower risk of thyroid dysfunction and confers greater improvement in left atrial remodelling."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Endocrine Disorders

Identification of cellular ion channels that facilitate Hazara nairovirus infection enables selection of clinically approved compounds with anti-nairoviral properties. (PubMed, Sci Rep) - "Consistent with this, we showed that clinically-approved K+ channel blockers quinidine, quinine and dronedarone and clinically-approved Ca2+ channel blockers tetrandrine and nifedipine significantly reduced HAZV activities. Biochemical experiments showed K+ expanded the pH range that promoted entry, potentially allowing endosome escape deeper within the endolysosomal network. These results show clinically-approved channel blockers effectively inhibit HAZV replication, suggesting repurposing existing therapies may represent promising avenues to block nairovirus infection."

Journal • Infectious Disease

Efficacy and Safety of Dronedar one in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial. (PubMed, J Cardiovasc Electrophysiol) - P3 | "Dronedarone is an effective AAD for patients with AF across a range of BMI categories with a manageable safety profile."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Obesity

Pharmacologic rhythm control for atrial fibrillation with dronedarone versus sotalol in patients with and without heart failure. (PubMed, Curr Probl Cardiol) - No abstract available

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

CONTINUATION VERSUS INTERRUPTION OF MAINTENANCE ANTIARRHYTHMIC THERAPY IN ADULT INTENSIVE CARE UNIT PATIENTS (ACC 2026) - "Background: For patients admitted to an intensive care unit (ICU), there is limited guidance regarding the management of maintenance antiarrhythmic drug (AAD) therapy such as flecainide, propafenone, dofetilide, dronedarone, and sotalol...For patients who developed unstable arrhythmias, acute treatment with direct current cardioversion (DCCV) or pharmacological therapy, such as amiodarone, beta or non-dihydropyridine calcium channel blockers, or digoxin, will be recorded... Research is currently ongoing with the objective of gaining insight to prescribing patterns and clinical outcomes."

Clinical • Cardiovascular • Critical care • Ventricular Tachycardia

ABLATION OF INTRA-ATRIAL REENTRANT TACHYCARDIA WITHIN THE LATERAL TUNNEL IN A PATIENT WITH FONTAN CIRCULATION (ACC 2026) - "Sotalol was precluded by prolonged QTc interval and dronedarone was trialed...Amiodarone was initiated; however, long term therapy was felt unfavorable due to younger age and co-existing liver disease... Patients with Fontan circulation have a proclivity for atrial arrhythmias, and AV dyssynchrony is poorly tolerated compared to two ventricle circulations. This case presents an example of successful intra-tunnel ablation of IART in a IALT Fontan with closed fenestrations."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology

PREPROCEDURAL CLASS III ANTIARRHYTHMIC THERAPY AND CONDUCTION DISTURBANCES AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) (ACC 2026) - "The effect of class III antiarrhythmic drugs (AADs; sotalol, amiodarone, dronedarone and dofetilide) on these complications remains unclear. Pre-procedural class III AAD use was associated with reduced new-onset AF following TAVI but did not significantly influence conduction disturbances or PPM implantation. Further prospective studies are needed to clarify their role in optimizing post-TAVI outcomes."

Atrial Fibrillation • Cardiovascular